Core Viewpoint - The release of the "Priority Approval Directory for High-end Medical Devices (2025 Edition)" by the National Medical Products Administration (NMPA) signifies a regulatory shift aimed at expediting the approval process for high-end medical technologies while ensuring safety and efficacy [2][3]. Summary by Relevant Sections Overview of Eight High-end Medical Devices - The directory includes eight categories of high-end medical devices spanning tumor radiotherapy, imaging equipment, interventional therapy, surgical robots, neuroregulation, and life support, indicating a focus on both cutting-edge technologies and established fields with clinical or technical gaps [2][4]. Significance of Priority Approval - "Priority approval" does not equate to lowered standards but represents a change in resource allocation within the regulatory framework, aiming to reduce unnecessary time costs while maintaining safety and efficacy [3][5]. - The directory serves as a starting point for technologies to enter a "key review perspective," facilitating earlier clinical validation and commercial data accumulation [3][5]. Implications for Companies - Companies can expect to engage in earlier technical communication with the review system, expedite critical registration milestones, and accelerate commercialization processes [5][6]. - The directory emphasizes the importance of entering verifiable and iterative clinical stages, which can enhance competitive advantages for companies [5][6]. Patient Accessibility - For patients, the priority approval means earlier access to advanced treatment technologies, which can support ongoing innovation by bringing commercial returns forward to fund high-risk medical device research [6][8]. Common Features of the Selected Products - The eight products share common characteristics that provide institutional support for long-term technological pathways rather than merely following market trends [7][8]. Conclusion - The publication of the directory marks the beginning of a collaborative regulatory and innovation process, with future observations focused on which technologies complete clinical validation first and how companies leverage their time advantages into long-term capabilities [8].

Core Viewpoint - The article discusses the approval and significance of the Boron Neutron Capture Therapy (BNCT) system developed by Guoke Neutron Medical Technology Co., Ltd., highlighting its potential as a new cancer treatment method with advanced precision and lower side effects [1][3][20]. R&D Background - BNCT is recognized as the "fifth cancer treatment method" after surgery, traditional radiotherapy, chemotherapy, and immunotherapy, particularly effective for hard-to-treat cancers like glioblastoma, head and neck cancer, and melanoma [2]. - The global BNCT market is estimated to be several hundred million dollars in 2023, with a projected CAGR of 10%-15% by 2030, primarily in Japan, the USA, and Europe [2]. - Japan's Sumitomo Heavy Industries and Stella Pharma launched the first BNCT device and boron drug in 2020, with treatment costs around tens of thousands of dollars per session [2]. About the BNCT System - The BNCT system developed by Guoke Neutron Medical Technology utilizes neutron and boron reactions to precisely kill tumor cells, marking the success of China's first self-owned intellectual property BNCT device [3][20]. - The device consists of a Radio Frequency Quadrupole (RFQ) accelerator, neutron generation system, and treatment room, designed to treat cancers that are difficult to manage with conventional methods [5]. Technical Analysis of BNCT - BNCT employs a two-pronged approach combining radiation and drug therapy, specifically targeting infiltrative and metastatic cancers [6]. - The treatment involves injecting boron-containing drugs that accumulate in tumor cells, followed by neutron irradiation, which leads to a nuclear reaction that effectively destroys cancer cells while sparing healthy tissue [9][13]. Advantages of BNCT - BNCT requires only 1-2 treatment sessions compared to over 30 sessions for conventional therapies, significantly reducing treatment duration [10][13]. - The treatment's precision is enhanced by the biological targeting of boron drugs, minimizing damage to surrounding healthy tissues [13]. Product Development History - The development of BNCT in China began in 2006 under the "973" program, with significant milestones achieved over the years, including the establishment of the first domestic RFQ accelerator and the successful installation of the first clinical BNCT device in Dongguan [14][15]. Company Overview - Guoke Neutron Medical Technology Co., Ltd. was established in 2021, focusing on the R&D, production, and marketing of high-end medical equipment for BNCT [20]. - The company has successfully completed clinical device design and testing, with high operational efficiency reported for its installed BNCT equipment [17][19].